Welcome to our dedicated page for Shattuck Labs news (Ticker: STTK), a resource for investors and traders seeking the latest updates and insights on Shattuck Labs stock.
Shattuck Labs, Inc. (STTK) is a clinical-stage biotechnology company developing innovative dual-function fusion proteins targeting cancer and autoimmune diseases. This page serves as the definitive source for official company announcements, research milestones, and financial updates.
Investors and industry professionals will find timely updates on STTK's clinical trials, regulatory developments, and strategic partnerships. The curated news collection includes press releases on pipeline advancements, collaborations with pharmaceutical leaders, and progress across its proprietary ARC® platform programs.
Key content categories include updates on lead candidates like SL-172154, financial reporting disclosures, and scientific presentations. All materials are sourced directly from company communications to ensure accuracy and compliance.
Bookmark this page for streamlined access to STTK's latest developments in bi-functional therapeutics. Check regularly for critical updates impacting the company's position in immuno-oncology and autoimmune treatment innovation.
Shattuck Labs, a clinical-stage biotechnology company listed on NASDAQ under the symbol STTK, announced its participation in the H.C. Wainwright BioConnect 2021 Conference, set for January 11-14, 2021. The presentation will be led by Andrew Neill, Vice President of Finance and Corporate Strategy, on January 11 at 6:00 a.m. EST. Attendees can access the session via a dedicated webcast link. Shattuck specializes in developing bi-functional fusion proteins for cancer and autoimmune disease treatments.
Shattuck Labs, a clinical-stage biotechnology company focused on bi-functional fusion proteins for cancer and autoimmune disease treatment, will present at the 39th Annual J.P. Morgan Healthcare Conference from January 11-14, 2021. CEO Taylor Schreiber will speak on January 14 at 5:20 p.m. EST. The presentation can be accessed live via webcast, with a replay available for 30 days. Shattuck's lead program is SL-172154, currently in Phase 1 trials, aiming to block the CD47 immune checkpoint while activating the CD40 pathway.
Shattuck Labs, a clinical-stage biotechnology firm, announced its inclusion in the Russell 2000® and 3000® Indexes effective December 21, 2020. This milestone is seen as a reflection of investor confidence and is expected to enhance the company's visibility in the investment community, expanding its institutional shareholder base. The Russell indexes, managed by FTSE Russell, are pivotal for asset managers, with about $9 trillion in assets benchmarked against them. Shattuck specializes in bi-functional fusion proteins targeting cancer and autoimmune diseases, including ongoing Phase 1 trials for lead programs.
Shattuck Labs, a clinical-stage biotechnology company focused on developing bi-functional fusion proteins, announced participation in the Evercore ISI 3rd Annual HealthCONx conference taking place December 1-3, 2020. The company's CEO, Taylor Schreiber, and VP of Finance, Andrew Neill, will participate in a fireside chat on December 2 at 1:00 p.m. EST. The event can be accessed via a live webcast, with a replay available for 90 days post-event. Shattuck's lead programs include SL-172154 and SL-279252, both undergoing Phase 1 trials for cancer treatment.
Shattuck Labs (NASDAQ: STTK) announced the initiation of a Phase 1 clinical trial for its CD47 checkpoint inhibitor, SL-172154, targeting ovarian cancer. The company raised approximately $232.3 million in its October 2020 IPO, extending its cash runway into 2024. Financial results for Q3 2020 show a net loss of $11.8 million, increasing from $7.3 million in Q3 2019. R&D expenses rose to $11.8 million, up from $7.9 million in the same period last year. Shattuck remains focused on advancing its clinical trials and maintaining its pipeline through ongoing funding.
Shattuck Labs, a clinical-stage biotechnology firm (NASDAQ: STTK), announced the presentation of preclinical data from its GADLEN™ platform at the SITC Annual Meeting on November 11, 2020. The research showcases the potential of a butyrophilin heterodimer to activate gamma delta T cells, targeting lymphoma cells with the CD19 antigen. CEO Taylor Schreiber emphasized the promise of enhancing gamma delta T cell effectiveness for treating resistant cancers. This milestone represents significant progress in developing GADLEN compounds for various tumor targets.
Austin, TX and Durham, NC – November 6, 2020 – Shattuck Labs (NASDAQ: STTK), a clinical-stage biotechnology company focused on bi-functional fusion proteins for cancer and autoimmune disease treatment, announced participation in the Cowen 4th Annual IO Next Summit on November 13, 2020. CEO Taylor Schreiber and senior executives will join a fireside chat with analyst Marc Frahm. The presentation is scheduled for 2:15 p.m. EST and can be accessed via a webcast. Shattuck's innovative ARC® platform develops therapies inhibiting immune checkpoints while activating costimulatory pathways.
Shattuck Labs (NASDAQ: STTK), a clinical-stage biotechnology company, announced its upcoming presentation at the virtual CD47|SIRPα Summit 2020 on November 5, 2020. The presentation, titled "CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade to Bridge Innate and Adaptive Immunity," will be delivered by CEO Taylor Schreiber at 10:45 a.m. EST. Shattuck is developing bi-functional fusion proteins targeting cancer and autoimmune diseases, with its lead program SL-172154 currently in a Phase 1 trial.
Shattuck Labs, a clinical-stage biotechnology company, will present at the TIGIT Therapies Digital Summit 2020 on October 26 at 10:00 a.m. EDT. The presentation, titled Using LIGHT to Hotwire TIGIT Blockade, will be led by CEO Taylor Schreiber. Shattuck is focused on developing bi-functional fusion proteins for cancer and autoimmune treatments through its unique ARC® platform. Their leading compound, SL-172154, is currently in a Phase 1 trial, alongside another compound, SL-279252, being tested with Takeda Pharmaceuticals. The presentation will be available for download on their website.
FAQ
What is the current stock price of Shattuck Labs (STTK)?
What is the market cap of Shattuck Labs (STTK)?
